Analyst picks & changes
By BC Staff | Mar 26, 2007 | 7:00 AM GMT
Analyst picks & changes
| Company | Bank | Analyst | Coverage | Opinion | Wk chg | 3/23 cls |
| 3SBio (SSRX) | Pacific Growth | Y. Katherine Xu | New | Buy | 9% | $11.85 |
| Xu's rating reflects SSRX's position as the erythropoietin (EPO) market leader in China. She thinks sales of EPIAO to treat anemia associated with kidney diseases, red cell mobilization and chemotherapy-induced anemia as well as sales of TPIAO to treat chemotherapy-induced thrombocytopenia could grow to $56M
|
Read the full 696 word article
